CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal targets and efficacy of these new agents. In this podcast, recorded at the Myeloma 2018 meeting in San Diego, CA, David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensac, NJ, chairs a discussion with Andrew Spencer, MBBS, FRACP, FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and Ravi Vij, MD, MBA, of Washington University Medical School, St. Louis, MO. They discuss the current landscape of CAR T-cell therapy, including exploratory targets, the cost vs. value of this treatment, and consider the question of where CAR T-cells will be best placed in the treatment sequence.